Rivoceranib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Rivoceranib
Accession Number
DB14765
Description

Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 397.482
Monoisotopic: 397.190260381
Chemical Formula
C24H23N5O
Synonyms
  • APATINIB

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Darbepoetin alfaThe risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Rivoceranib.
ErythropoietinThe risk or severity of Thrombosis can be increased when Erythropoietin is combined with Rivoceranib.
Methoxy polyethylene glycol-epoetin betaThe risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Rivoceranib.
PeginesatideThe risk or severity of Thrombosis can be increased when Peginesatide is combined with Rivoceranib.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
5S371K6132
CAS number
811803-05-1
InChI Key
WPEWQEMJFLWMLV-UHFFFAOYSA-N
InChI
InChI=1S/C24H23N5O/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30)
IUPAC Name
N-[4-(1-cyanocyclopentyl)phenyl]-2-{[(pyridin-4-yl)methyl]amino}pyridine-3-carboxamide
SMILES
O=C(NC1=CC=C(C=C1)C1(CCCC1)C#N)C1=CC=CN=C1NCC1=CC=NC=C1

References

General References
Not Available
ChemSpider
9490441
ChEMBL
CHEMBL3186534
ZINC
ZINC000070466461
Wikipedia
Apatinib

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentBreast Cancer / Cervical Cancers / Esophageal Cancers / Malignancies / Malignant Neoplasm of Stomach / Non-Small Cell Lung Carcinoma (NSCLC) / Ovarian Cancer1
4CompletedTreatmentDiffuse Large B-Cell Lymphoma (DLBCL) / Relapsed /Refractory Diffuse Large B Cell Lymphoma / Relapsed and Refractory1
4Not Yet RecruitingTreatmentAdvanced Non-squamous Non-small-cell Lung Cancer1
4Not Yet RecruitingTreatmentLung Squamous Cell Carcinoma1
4RecruitingOtherStage IV Cancer1
4RecruitingTreatmentMalignant Neoplasm of Stomach1
4RecruitingTreatmentNewly Diagnosed Peripheral T-cell Lymphoma1
3Active Not RecruitingTreatmentDifferentiated Thyroid Cancer (DTC)1
3Active Not RecruitingTreatmentGastric Adenocarcinoma / Malignant Neoplasm of Stomach1
3Active Not RecruitingTreatmentHepatocellular Carcinoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.012 mg/mLALOGPS
logP3.14ALOGPS
logP4.29ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)15.23ChemAxon
pKa (Strongest Basic)5.41ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area90.7 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity119.16 m3·mol-1ChemAxon
Polarizability43.36 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on May 20, 2019 08:25 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates